DelveInsight has launched a new report on “Chronic Spontaneous Urticaria – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Chronic Spontaneous Urticaria – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Chronic Spontaneous Urticaria Market Report:

• Age plays an important role in the case of Chronic Spontaneous Urticaria (CSU) as it is most common in older adults. In 2020, there were 45,853 cases in the age group of fewer than 19 years and 99,629 cases in the age group of 60 to 69 years which are expected to rise to 49,547 cases and 107,656 cases respectively in 2030 in the US.
• Among the European countries, Germany had the highest prevalent population of 122,708 cases, followed by France which had a prevalent population of 103,819 in 2020. 
• In 2020, prevalent cases of Chronic Spontaneous Urticaria in the US varied according to gender; such as for Females- 373,163 and 138,019 for males respectively which are expected to increase in the forecasted period. 

Key benefits of the report:

1. Chronic Spontaneous Urticaria market report covers a descriptive overview and comprehensive insight of the Chronic Spontaneous Urticaria Epidemiology and Chronic Spontaneous Urticaria  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Chronic Spontaneous Urticaria market report provides insights on the current and emerging therapies.
3. Chronic Spontaneous Urticaria market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Chronic Spontaneous Urticaria market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Spontaneous Urticaria market.

Got queries? Click here to know more about the Chronic Spontaneous Urticaria Market Landscape.

Chronic Spontaneous Urticaria Overview

Chronic spontaneous urticaria (CSU) or Chronic Idiopathic urticaria (CIU) is defined as persistent symptoms of urticaria for 6 weeks or more.  It is a distressing skin condition that causes red, swollen, itchy, and sometimes painful hives or “wheals” on the skin. It is associated with autoimmunity in almost half of the cases, but the remaining cases still remain “idiopathic,” and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous and is independent of any external physical stimulus, which is conceptually helpful and does not imply knowing or not knowing the cause. 

Chronic Spontaneous Urticaria Market 

The dynamics of the Chronic Spontaneous Urticaria market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Novartis, Sanofi, Genentech, Kiniksa Pharmaceuticals, and others during the forecasted period 2018-2030.

Learn more by requesting for sample @ Chronic Spontaneous Urticaria Market Landscape 

Chronic Spontaneous Urticaria Pipeline Therapies and Key Companies 

• Ligelizumab: Novartis
• Dupilumab: Sanofi
• Fenebrutinib: Genentech 
• Vixarelimab: Kiniksa Pharmaceuticals

Chronic Spontaneous Urticaria Market Drivers 

• Treatment Side Effects With Currently Available Treatment
• Economic Burden On Patients
• Increase in Research and Development Activities
• Increasing Market Size

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Chronic Spontaneous Urticaria Patient Share (%) Overview at a Glance

5. Chronic Spontaneous Urticaria Market Overview at a Glance

6. Chronic Spontaneous Urticaria Disease Background and Overview

7. Chronic Spontaneous Urticaria Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Spontaneous Urticaria 

9. Chronic Spontaneous Urticaria Current Treatment and Medical Practices

10. Unmet Needs

11. Chronic Spontaneous Urticaria Emerging Therapies

12. Chronic Spontaneous Urticaria Market Outlook

13. Country-Wise Chronic Spontaneous Urticaria Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Chronic Spontaneous Urticaria Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Chronic Spontaneous Urticaria Pipeline 

“Chronic Spontaneous Urticaria Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Spontaneous Urticaria market. A detailed picture of the Chronic Spontaneous Urticaria pipeline landscape is provided, which includes the disease overview and Chronic Spontaneous Urticaria treatment guidelines.

Chronic Spontaneous Urticaria Epidemiology

DelveInsight’s ‘Chronic Spontaneous Urticaria  Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Spontaneous Urticaria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/